Anesthesia in patients with cancer disorders

Current Opinion in Anaesthesiology

Volumn 25, Issue 3, 2012, Pages 376-384

  Kurosawa, Shin ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

anesthesia; cancer; immunosuppression; surgery

Indexed keywords

ANESTHETIC AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MORPHINE; MU OPIATE RECEPTOR; OPIATE; PROPOFOL; PROSTAGLANDIN SYNTHASE INHIBITOR; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANESTHESIA; BLOOD TRANSFUSION; BREAST CANCER; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; GENERAL ANESTHESIA; HUMAN; HYPERGLYCEMIA; HYPOTENSION; HYPOTHERMIA; HYPOVOLEMIA; HYPOXIA; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS ANESTHESIA; METASTASIS; NATURAL KILLER CELL; NEOPLASM; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; RECTUM CANCER; REGIONAL ANESTHESIA; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR IMMUNITY;

ANESTHESIA; ANESTHESIA, CONDUCTION; ANESTHETICS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNITY, CELLULAR; IMMUNOMODULATION; IMMUNOSUPPRESSION; KILLER CELLS, NATURAL; NEOPLASMS; NUTRITIONAL SUPPORT; PERIOPERATIVE CARE;

EID: 84861031863     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e328352b4a8     Document Type: Review

References (118)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials. Lancet 2011;378:1707-1716.
2. Vallejo R, Hord ED, Barna SA, et al. Perioperative immunosuppression in cancer patients. J Environ Pathol, Tox 2003;22:139-146.
3. Kurosawa S, Kato M. Anesthetics, immune cells, and immune responses. J Anesth 2008;22:263-277.
4. Meiler SE. Long-term outcome after anesthesia and surgery: remarks on the biology of a newly emerging principle in perioperative care. Anesthesiology Clin N Am 2006;24:255-278.
5. Homburger JA, Meiler SE. Anesthesia drugs, immunity, and long-term outcome. Curr Opin Anesthesiol 2006;19:423-428.
6. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-148.
7. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's role in cancer suppression and promotion. Science 2011;331:1565-1570. This excellent review describes the mechanisms of cancer immunoescape and its development under the concept of cancer immunoediting.
8. Lindholm ML, Granath F, Eriksson LI, et al. Malignant disease within 5 years after surgery in relation to duration of sevoflurane anesthesia and time with bispectral index under 45. Anesth Analg 2011;113:778-783. This is the first clinical study designed under the concept of cancer immunoediting.
9. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-728.
10. Zammaron BF, Chen WJ. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011;7:651-658.
11. Mantovani A, Marchesi F, Porta Chiara, et al. Inflammation and cancer: breast cancer as a prototype. Breast 2007;16:S27-S33.
12. Goldfarb Y, Sorski L, Benish M, et al. Improving postoperative immune status and resistance to cancer metastasis. Ann Surg 2011;253:798-810. An animal study which analyzed the role of catecholamines and prostaglandins in the perioperative immunosuppression and the postoperative tumor progression.
13. Yaguchi T, Sumimoto H, Kudo-Saito C, et al. The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol 2011;93:294-300.
14. Stojanovic A, Cerwenka A. Natural killer cells and solid tumors. J Innate Immun 2011;3:355-364.
15. Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 2011;60:1161-1171.
16. + T cells in antitumor immune responses. Immunol Rev 2008;222:129-144.
17. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-899.
18. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-237.
19. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-4506.
20. Jouce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature Rev Cancer 2009;9:239-252.
21. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 2007;13:5243-5248.
22. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011;140:1807-1816.
23. Inada T, Kubo K, Shingu K. Possible link between cyclooxygenase- inhibiting and antitumor properties of propofol. J Anesth 2011;25:569-575. This review provides the possible role of propofol as a cyclooxygenase inhibitor to prevent the perioperative suppression of antitumor immunity.
24. Kuroda E, Yamashita U. Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominnt BALB/c mice. J Immunol 2003;170:757-764.
25. Becker Y. Molecular Immunological approaches to biotherapy of human cancers-A review, hypothesis and implications. Anticancer Res 2006;26:1113-1134.
26. Evans C, Galustian C, Kumar D, et al. Impact of surgery on immunologic function: comparison between minimally invasive techniques and conventional laparotomy for surgical resection of colorectal tumors. Am J Surg 2009;197:238-245.
27. Ishikawa M, Nishioka M, Hanaki N, et al. Perioperative immune responses in cancer patients undergoing digestive surgeries. World J Surg Oncol 2009;7:7.
28. Gottschalk A, Sharma S, Ford J, et al. The role of the perioperative period in recurrence after surgery. Anesth Analg 2010;110:1636-1643.
29. Uotila P. The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer. Cancer Immunol Immunother 1996;42:1-9.
30. Glasner A, Avraham R, Rosenne E, et al. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a b-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 2010;184:2449-2457.
31. Levi B, Benish M, Goldfarb Y, et al. Continuous stress disrupts immunostimulatory effect of IL-12. Brain Behav Immun 2011;25:727-735.
32. Dimitrov A, Lange T, Born J. Selective mobilization of cytotoxic leukocytes by epinephrine. J Immunol 2010;184:503-511.
33. Eskandari F, Stemberg EM. Neural-immune interactions in health and disease. Ann N Y Acad Sci 2002;966:20-27.
34. Hogan BV, Peter MB, Shenoy HG, et al. Surgery induced immunosuppression. Surgeon 2011;9:38-43.
35. van Meurs M, Wulfelt FM, Jongman RM, et al. Hemorrhagic shock-induced endothelial cell activation in a spontaneous breathing and a mechanical ventilation hemorrhagic shock model is induced by a proinflammatory response and not by hypoxia. Anesthesiology 2011;115:474-482.
36. Eitzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011;364:656-665. An excellent review summarizing the mechanisms by which hypoxia promotes inflammation and inhibits Th1 polarization.
37. Brahimi-Horn MC, Chiche J, Poussegur J. Hypoxia and cancer. J Mol Med 2007;85:1301-1307.
38. Younes RN, Rogatko A, Brennan MF. The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases. Ann Surg 1991;214:107-113.
39. Forbes SS, Eskicioglu C, Nathens AB, et al. Evidence-based guidelines for prevention of perioperative hypothermia. J Am Coll Surg 2009;209:492-503.
40. Qadan M, Gardner SA, Vitale DS, et al. Hypothermia and surgery. Ann Surg 2009;250:134-140.
41. Yücel Y, Barlan M, Lenhardt R, et al. Perioperative hypothermia does not enhance the risk of cancer dissemination. Am J Surg 2005;189:651-655.
42. Ben-Eliyahu S, Shakhar G, Rosenne E, et al. Hypothermia in barbiturateanesthetized rats suppresses natural killer activity and compromises resistance to tumor metastasis. Anesthesiology 1999;91:732-740.
43. Makino T, Kato K, Mizukami H. Processed aconite root prevents cold-stressinduced hypothermia and immuno-suppression. Biol Pharm Bull 2009;32:1741-1748.
44. Torossian A. Thermal management during anaesthesia and thermoregulation standards for the prevention of inadvertent perioperative hypothermia. Best Pract Clin Anaesthesiol 2008;22:659-668.
45. Ramos M, Khalpey Z, Lipsitz S, et al. Relationship of perioperative hyperglycemia and postoperative infections in patients who undergo general and vascular surgery. Ann Surg 2008;248:585-591.
46. Turina M, Fry DE, Polk HC. Acute hyperglycemia and innate immune system: clinical, cellular, and molecular aspects. Crit Care Med 2005;33:1624-1633.
47. Turina M, Miller FN, Tucker CF. Short-term hyperglycemia in surgical patients and a study of related cellular mechanisms. Ann Surg 2006;243:845-853.
48. Hanazaki K, Maeda H, Okabayashi T. Relationship between perioperative glycemic control and postoperative infection. World J Gastroenterol 2009;15:4122-4125.
49. Wasmuth HE, Kunz D, Graf J, et al. Hyperglycemia at admission to the intensive care unit is associated with elevated serum concentrations of interleukin-6 and reduced ex vivo secretion of tumor necrosis factor-a. Crit Care Med 2004;1109-1114.
50. Collier B, Dossett LA, May AK, et al. Glucose control and the inflammatory response. Nutr Clin Pract 2008;23:3-15.
51. Deng H, Chai J. The effects and mechanisms of insulin on systemic inflammatory response and immune cells in severe trauma, burn injury, and sepsis. Int Immunopharmacol 2009;9:1251-1259.
52. Akhtar S, Barash PG, Inzucchi SE. Scientific principles and clinical implications of perioperative glucose regulation and control. Anesth Analg 2010;110:478-497.
53. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev 2003;21:327-348.
54. Baumgartner JM, Silliman CC, Moore EE, et al. Stored red blood cell transfusion induces regulatory T cells. J Am Coll Surg 2009;208:110-119.
55. Amato A, Pescatori M. Perioperative blood transfusion for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006;1:CD005033.
56. Bernard A, Meier C, Ward M, et al. Packed red blood cells suppress T-cell proliferation through a process involving cell-cell contact. J Trauma 2010;69:320-329.
57. Waanders MM, Roelen DL, Brand A, et al. The putative mechanism of the immunomodulating effect of HLA-DR shared allogeneic blood transfusions on the alloimmune response. Transfusion Med Rev 2005;19:281-287.
58. Weber RS, Jabbour N, Martin RCG II. Anemia and transfusions in patients undergoing surgery for cancer. Ann Surg Oncol 2008;15:34-45.
59. Greenfeld K, Avraham R, Benish M, et al. Immune suppression while awaiting surgery and following it: dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav Immun 2007;21:503-513.
60. Shang ZJ, Liu K, Liang DF. Expression of beta (2)-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 2009;38:371-376.
61. Powe DG, Voss MJ, Zänker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010;1:628-638. A clinical study which demonstrates the usefulness of beta-blocker to reduce breast cancer recurrence and metastasis.
62. Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003;9:4514-4521.
63. Sacerdote P. Opioid-induced immunosuppression. Curr Opin Support Palliat Care 2008;2:14-18.
64. Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptordependent signaling and behavior. Anesthesiology 2011;115:1363-1381.
65. Martin JL, Koodie L, Krishnan AG, et al. Chronic morphine administration delays wound healing by inhibiting immune cell recruitment to the wound site. Am J Pathol 2010;176:786-799.
66. Welters ID, Menzebach A, Goumon Y, et al. Morphine suppresses complement receptor expression, phagocytosis, and respiratory burst in neutrophils by a nitric oxide and m3 oipate receptor-dependent mechanism. J Neuroimmunol 2000;111:139-145.
67. Bilfinger TV, Fimiani C, Stefano GB. Morphines immunoregulatory actions are not shared by fentanyl. J Cardiol 1998;64:561-566.
68. Mojadadi S, Jamali A, Khansarinejad B, et al. Acute morphine administration reduces cell-mediated immunity and induces reactivation of latent herpes simplex virus type 1 in BALB/c mice. Cell Mol Immunol 2009;6:111-116.
69. Börner C, Warnick B, Smida M, et al. Mechanisms of opioid-mediated inhibition of human T cell receptor signaling. J Immunl 2011;183:882-889.
70. Wang J, Barke RA, Charboneau R, et al. Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J Biol Chem 2003;278:37622-37631.
71. + T cell IL-4 expression through an adenylyl cyclase mechanism independent of the protein kinease A pathway. J Immunol 2005;175:6361-6367.
72. Börner C, Kraus J, Bedini A, et al. T-cell receptor/CD28-mediated activation of human T lymphocytes induces expression of functional m-opioid receptors. Mol Pharmacol 2008;74:496-504.
73. Chen C, Farooqui M, Gupta K. Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells. Curr Neurovasc Res 2006;3:171-180.
74. Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002;62:4491-4498.
75. Fujioka N, Nguyen J, Chen C, et al. Morphine-induced epidermal growth factor pathway activation in nonsmall cell lung cancer. Anesth Analg 2011;113:1353-1364. A novel interesting finding about the morphine-induced tumor progression via interaction of morphine and m-opioid receptors.
76. Ecimovic P, Murray D, Doran P, et al. Direct effect of morphine on breast cancer cell function in vitro: role of the NET1 gene. Br J Anaesth 2011;107:916-923.
77. Singleton PA, Lingen MW, Fekete JG, et al. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Micrivasc Res 2006;72:3-11.
78. Wang CZ, Li XL, Sun S, et al. Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells. Anticancer Res 2009;29:2927-2932.
79. Mathew B, Lennon FE, Siegler J, et al. The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 2011;112:558-567.
80. Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001;90:191-199.
81. + lymphocytes in human. Anesth Analg 2002;94:94-99.
82. Cronin AJ, Aucutt-Walter NM, Budinetz T, et al. Low-dose remifentanil infusion does not impair natural killer function in healthy volunteers. Br J Anaesth 2003;91:805-809.
83. Melamed R, Bar-Yosef S, Shakhar G, et al. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not propofol: mediating mechanisms and prophylactic measures. Anesth Analg 2003;97:1331-1339.
84. Markovic SN, Knight PR, Murasko DM, et al. Inhibition of interferon stimulation of natural killer cell activity in mice anesthetized with halothane or isoflurane. Anesthesiolog 1993;78:700-706.
85. Wada H, Seki S, Takahashi A, et al. Combined spinal and general anesthesia attenuates liver metastasis by preserving TH1/TH2 cytokine balance. Anesthesiology 2007;106:499-506.
86. Matsuoka H, Kurosawa S, Horinouchi T, et al. Inhalation anesthetics induce apoptosis in normal peripheral lymphocytes in vitro. Anesthesiology 2001;95:1467-1472.
87. Loop T, Dovi-Akue D, Frick M, et al. Volatile anesthetics induce caspasedependent, motochondria-mediated apoptosis in human T lymphocytes in vitro. Anesthesiology 2005;102:1147-1157.
88. Loop T, Scheiermann P, Doviakue D, et al. Sevoflurane inhibits phorbolmyristateacetate-induced activator protein-1 activation in human T lymphocytes in vitro: potential role of the p38-stress kinase pathway. Anesthesiology 2004;101:710-721.
89. Zhou Y, Li E, Liu S. Attenuating sevoflurane-induced cellular injury of human peripheral lymphocytes by propofol in a concentration dependent manner. Arch Pharm Res 2011;34:1534-1543. This in-vitro study showed the mechanisms by which propofol protects lymphocytes from sevoflurane-induced apoptosis.
90. Wei H, Xie Z. Anesthesia, calcium homeostasis and Alzheimer's disease. Curr Alzheimer Res 2009;6:30-35.
91. Tanaka K, Kawano T, Tomino T, et al. Mechanisms of impaired glucose tolerance and insulin secretion during isoflurane anesthesia. Anesthesiology 2009;111:1044-1051.
92. Nicholson G, Hall GM. Effects of anaesthesia on the inflammatory response to injury. Curr Opin Anesthesiol 2011;24:370-374.
93. Kawaraguchi Y, Horikawa YT, Murphy AN, et al. Volatile anesthetics protect cancer cells against tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via caveolins. Anesthesiology 2011;115:499-508. The results of this study showed that isoflurane exposure leads to resistance against tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in colon cancer cell lines in vitro.
94. Inada T, Kubo K, Shingu K. Vaccines using dendritic cells, differentiated with propofol, enhance antitumor immunity in mice. Immunopharmacol Immunotoxicol 2009;31:150-157.
95. Braz MG, Magalhaes MR, Salvadori DM, et al. Evaluation of DNA damage and lipoperoxidation of propofol in patients undergoing elective surgery. Eur J Anaesthesiol 2009;26:654-660.
96. Ren XF, Li WZ, Meng FY. Differential effects of propofol and isoflurane on the activation of T-helper cells in lung cancer patients. Anaesthesia 2010;65:478-482.
97. Tylman M, Sarbinowski R, Bengtson JP, et al. Inflammatory response in patients undergoing colorectal cancer surgery: the effect of two different anesthetic techniques. Minerva Anesthesiol 2011;77:275-282.
98. Ji F, Wang Y, Yang J. Effects of propofol anesthesia and sevoflurane anesthesia on the differentiation of human T-helper cells during surgery. Chin Med J 2011;124:525-529.
99. Inada T, Yamanouchi Y, Jomura S, et al. Effect of propofol and isoflurane anaesthesia on the immune response to surgery. Anaesthesia 2004;59:954-959.
100. Kushida A, Inada T, Shingu K. Enhancement of antitumor immunity after propofol treatment in mice. Immunopharmacol Immunotoxicol 2007;29:477-486.
101. Rizzo MT. Cyclooxygenase-2 in oncogenesis. Clin Chim Acta 2011;412:671-687.
102. Farooqui M, Li Y, Rogers T, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumor growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007;97:1523-1531.
103. Forget P, Vandenhende J, Berliere M, et al. Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. Anesth Analg 2010;110:1630-1635.
104. Ohta N, Ohashi Y, Takayama C, et al. Midazolam suppresses maturation of murine dendritic cells and priming of lipopolysaccharide-induced T helper 1-type immune response. Anesthesiology 2011;114:355-362.
105. Ohta N, Ohashi Y, Fujino Y. Ketamine inhibits maturation of bone marrowderived dendritic cells and priming of the Th1-type immune response. Anesth Analg 2009;109:793-800.
106. Son KA, Kang JH, Yang MP. Ketamine inhibits the phagocytic responses of canine peripheral blood polymorphonucler cells through the upregulation of prostaglandin E2 in peripheral blood mononuclear cells in vitro. Res Vet Sci 2009;87:41-46.
107. Myles PS, Peyton P, Silbert B, et al. Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomized trial. Br Med J 2011;342:d1491. This prospective randomized controlled clinical trial (n=503 patients) demonstrates that epidural block in abdominal surgery for cancer does not improve cancer-free survival.
108. Exadaktylos AK, Buggy DJ, Miriarty DC, et al. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology 2006;105:660-664.
109. Biki B, Mascha E, Moriarty DC, et al. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence. Anesthesiology 2008;109:180-187.
110. Gupta A, Björnsson A, Fredriksson M, et al. Reduction in mortality after epidural anaesthesia and analgesia in patients undergoing rectal but not colonic cancer surgery: a retrospective analysis of data from 655 patients in central Sweden. Br J Anaesth 2011;107:164-170. This retrospective analysis provides the positive effect of epidural anesthesia on the mortality in patients with rectal cancer but not colonic cancer.
111. Lin L, Liu C, Tan H, et al. Anaesthetic technique may affect prognosis for ovarian serous adenocarcinoma: a retrospective analysis. Br J Anaesth 2011;106:814-822.
112. Wuethrich PY, Schmitz SFH, Kessler TM, et al. Potential influence of the anesthetic technique used during open radical prostatectomy on prostate cancer-related outcome. Anesthesiology 2010;113:570-576.
113. Christopherson R, James KE, Tableman M, et al. Long-term survival after colon cancer surgery: a variation associated with choice of anesthesia. Anesth Analg 2008;107:325-332.
114. Gottschalk A, Ford JG, Regelin CC, et al. Association between epidural analgesia and cancer recurrence after colorectal cancer surgery. Anesthesiology 2010;113:27-34.
115. Tsui BCH, Rashiq S, Schopflocher D, et al. Epidural anesthesia and cancer recurrence rates after radical prostatectomy. Can J Anesth 2010;57:107-112.
116. Ismail H, Ho KM, Narayan K, et al. Effect of neuraxial anaesthesia on tumour progression in cervical cancer patients treated with brachytherapy: a retrospective cohort study. Br J Anaesth 2010;105:1450149.
117. Suzuki D, Furukawa K, Kimura F, et al. Effects of perioperative immunonutrition on cell-mediated immunity, T helper type 1 (Th1)/Th2 differentiation, and Th17 response after pancreaticoduodenectomy. Surgery 2010;148:573-581.
118. Matsuda A, Furukawa K, Takahashi, et al. Preoperative oral immuneenhancing nutritional supplementation corrects TH1/TH2 imbalance in patients undergoing elective surgery for colorectal cancer. Dis Colon Rectum 2006;49:507-516.